NCT00856713View on ClinicalTrials.gov

Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 31, 2006

Conditions
Hepatic Cirrhosis
Interventions
DRUG

NRL972

Single intravenous dose of 2 mg NRL972

DRUG

NRL972

Single intravenous dose of 2 mg NRL972

DRUG

NRL972

Single intravenous dose of 2 mg NRL972

DRUG

NRL972

Single intravenous dose of 2 mg NRL972

DRUG

NRL972

Single intravenous dose of 2 mg NRL972

DRUG

NRL972

Single intravenous dose of 2 mg NRL972

Trial Locations (1)

1431

UMHAPT St Ivan Rilski's University Hospital, Sofia

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY